An Open Label Extension Study to Evaluate the Safety, Tolerability and Pharmacokinetics of STX209 in Subjects With Fragile X Syndrome
Overview
- Phase
- Phase 2
- Intervention
- Arbaclofen
- Conditions
- Fragile X Syndrome
- Sponsor
- Seaside Therapeutics, Inc.
- Enrollment
- 45
- Locations
- 9
- Primary Endpoint
- Irritability subscale of the Aberrant Behavior Checklist
- Status
- Terminated
- Last Updated
- 13 years ago
Overview
Brief Summary
Study 22001, "A Double-Blind, Placebo-Controlled, Flexible-Dose Evaluation of the Efficacy, Safety, and Tolerability of STX209 in the Treatment of Irritability in Subjects with Fragile X Syndrome" currently is evaluating the efficacy of STX209 (R-baclofen) for management of typical problem behaviors, such as irritability and aggression, in subjects with FXS. This study (22002) will enter subjects who complete Study 22001 into a long-term, open-label study.The open-label extension protocol will provide necessary data on the long-term safety and tolerability of STX209 among subjects with FXS who receive treatment under conditions more closely reflective of their general medical care.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Have completed all scheduled visits in protocol 22001 and have shown they can adequately follow the protocol, with sufficient medical justification to continue on open-label treatment with STX209, as assessed by the principal investigator
Exclusion Criteria
- •Subjects with a medical condition that might interfere with the conduct of the study, confound interpretation of the study results, or endanger their own well-being.
- •The occurrence or continuation of any adverse event or condition during study 22001 that, in the opinion of the Investigator, should exclude the subject from participating in this open-label extension.
Arms & Interventions
STX209
Intervention: Arbaclofen
Outcomes
Primary Outcomes
Irritability subscale of the Aberrant Behavior Checklist
Time Frame: 1 year